Patients with cirrhosis and hepatitis C virus (HCV) infection treated with direct-acting antivirals (DAAs) are still at risk for developing hepatocellular carcinoma (HCC). We aimed to identify features of de novo or recurrent HCCs in these patients, and factors associated with HCC development, in a large cohort of patients with cirrhosis who received treatment with DAAs.
T he achievement of a sustained virologic response (SVR) to antiviral treatment for hepatitis C virus (HCV) has been shown to prevent liver-related complications in patients with HCV-related cirrhosis. [1] [2] [3] Directacting antivirals (DAA) have improved treatment effectiveness in patients with cirrhosis, because of higher SVR rates and optimal drug safety profile, allowing HCV treatment scaling up in patients suffering from advanced cirrhosis. However, first reports concerning hepatocellular carcinoma (HCC) risk in patients with cirrhosis treated with DAAs have shown conflicting results: indeed, some studies showed a protective SVR effect on HCC development, [4] [5] [6] whereas others pointed out unexpected high rates of HCC after the SVR. Particular concern was raised both in patients without previous history of HCC (de novo HCC), but especially in patients with a previous HCC history (recurrent HCC), because some studies underlined a strict time relationship between DAA treatment and HCC recurrence. [7] [8] [9] [10] More recently, 2 large retrospective cohort studies have mitigated previous findings, confirming the protective SVR effect on HCC risk in HCV patients with cirrhosis treated with DAAs. 11, 12 In addition, a metanalysis by Waziry et al 13 failed to show substantial differences between HCC occurrence and recurrence in patients receiving interferon-or DAA-based therapy, although high heterogeneity of data limited the strength of the conclusions. However, evidences coming from many studies may suffer from some limitations, such as retrospective design, short follow-up data, and lack of regular HCC surveillance (Supplementary Tables 1 and 2) . Moreover, because of these methodologic limitations, many works were unable to provide precise information about HCC features and carefully investigate predictors of HCC onset. With this in mind, we conducted a single-center longitudinal 3-year study to assess incidence, features, and predictors of de novo and recurrent HCC in a large cohort of HCV patients with cirrhosis treated with DAAs.
Methods

Patient Population
Consecutive HCV patients with cirrhosis starting DAA treatment between December 2014 and 2016 at a single hepatology center were enrolled. Exclusion criteria were Child-Pugh-Turcotte (CPT) C score, whose treatment was not reimbursed by Italian National Health System outside the liver transplant waiting list; human immunodeficiency virus coinfection; and active HCC at baseline (DAA start), whose treatment was not allowed by Italian prescription rules. Patients with baseline atypical or uncharacterized (nodule size <1 cm or diagnostic algorithm not concluded) liver nodules according to 2012 HCC EASL recommendations were also excluded.
14 Cirrhosis was diagnosed either clinically (blunted nodular liver edges at ultrasound [US] scan AE splenomegaly þ platelet count below 150 Â 10 3 /mL), histologically (METAVIR F4), or noninvasively by transient elastography. Liver stiffness measurement (LSM) >11.9 kPa was the cutoff for cirrhosis. 15 Patients consented to make available their medical records for the study, whose protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki.
Treatment Monitoring and Post-treatment Follow-Up
Patients were assessed with complete blood examinations and HCV-RNA quantification every 4 weeks ontreatment; at post-treatment weeks 4, 12, and 24; and at 6-month intervals thereafter. SVR was defined as undetectable HCV-RNA 12 weeks after the end of treatment, according to Abbott-RT PCR (lower limit of detection 12 IU/mL).
Hepatocellular Carcinoma Surveillance and Management
HCC surveillance was performed by US scan every 6 months in patients with no previous HCC history or with a complete response (CR) to a previous HCC treatment >2 years; patients with a CR 2 years performed a computed tomography every 3 months. CR was defined as 2 consecutive negative imaging assessments following HCC treatment (computed tomography scan performed 1 and 3 months after HCC treatment according to mRE-CIST criteria). In patients under US-based HCC surveillance, baseline US scan was performed within 3 months before DAA start. As a consequence, all patients included in the study had at least 1 radiologic examination performed in the 3 months preceding DAA start, because absence of HCC or CR to a previous HCC treatment was required by Italian prescription rules to receive antiviral therapy. According to the previously mentioned exclusion criteria, all patients with baseline imaging showing a focal lesion (either atypical or uncharacterized nodule) were excluded from the study.
HCC was diagnosed, staged, and treated according to international recommendations. 16 
Noninvasive Markers of Fibrosis
Transient elastography was performed as already described.
17 Additional noninvasive markers of fibrosis, such as aspartate aminotransferase to platelet ratio, Fibrosis-4 (FIB-4) score, and the liver stiffness-spleen size-to-platelet ratio risk score, was assessed as previously described.
18,19
Statistical Analysis
Categorical variables were reported as frequencies (percentages) and continuous variables as median (range). Categorical variables were compared using the chi-square or the Fisher exact tests, and continuous variables by the Student t test, the Mann-Whitney U test, or the Kruskal-Wallis test, when appropriate. All tests were 2-sided and used a significance level of 0.05. Cumulative incidence of de novo or recurrent HCC was calculated according to the Kaplan-Meier method, and difference between groups was assessed with the logrank test. Univariate and multivariable Cox proportional hazards regression analysis was used to assess the baseline predictors of the development or recurrence or HCC during the study period. Data handling and analysis were performed with StataView package (SAS Institute Inc, Cary, NC).
Results
Baseline Patient Characteristics
This study includes 565 HCV CPT A-B patients with cirrhosis starting DAA between December 2014 and 2016 and followed for a median of 25 (3-39) months after DAA start: 505 patients had no previous HCC history, and 60 patients had a previous HCC (Figure 1 ). The baseline patient characteristics are shown in Table 1 . Overall, median age was 64 (28-87) years, 60% were males, and 87% had CPT score A. Among CPT A patients, 14 (2.4%) had history of previous ascites, occurring 24 (6-48) months before antiviral treatment start. Cirrhosis was defined clinically in 23% patients, histologically in 21%, and by LSM in 56%. The most common HCV genotype was 1b in 49%, and 56% patients had failed a previous interferon-based HCV treatment. a-Fetoprotein (AFP) at baseline was 9 (1-537) ng/mL.
Among the 60 patients with history of HCC, previous HCC was diagnosed 27 (4-186) months before DAA start: HCC size was 20 (5-60) mm, single in 85% patients. CPT score was A in 98% of patients, Barcelona Clinic Liver Cancer (BCLC) stage 0-A in 92%, and AFP was 11 (1-105) ng/ml. Fifty-five (92%) patients had received a curative HCC treatment; 73% achieved a CR after 1 single HCC treatment. Median time between last HCC treatment and DAA start was 12 (4-163) months (Supplementary Table 3 ).
Direct-Acting Antivirals Treatment and Effectiveness
Patients were treated according to EASL 2015 and National Health System recommendations: sofosbuvir/ledipasvir was prescribed in 212 patients, ombitasvir/paritaprevir/ritonavir þ dasabuvir in 140, sofosbuvir þ ribavirin in 78, sofosbuvir þ daclatasvir in 62, sofosbuvir þ simeprevir in 40, and ombitasvir/ paritaprevir/ritonavir in 33. Ribavirin-containing 
What You Need to Know
Background Incidence and predictors of hepatocellular carcinoma (HCC) after treatment of hepatitis C (HCV) cirrhosis with direct-acting antivirals (DAA) are still debated. Aim of the study was to identify features and predictors of de novo or recurrent HCC in a large cohort of HCV cirrhotics receiving DAA.
Findings
In a large, consecutive, single-center cohort of 565 HCV cirrhotic patients, the 3-year estimated cumulative probabilities of de novo and recurrent HCC were 6% and 43%, respectively. Both de novo and recurrent HCC were mostly small, single and qualified for curative treatments; male gender, diabetes and non-invasive markers of liver fibrosis predicted de novo HCC, while diabetes predicted HCC recurrence.
Implications for patient care HCV cirrhotic patients achieving a sustained virologic response (SVR) to DAA treatment should continue HCC surveillance due to residual HCC risk. Increased attention should be kept in patients carrying risk factors for HCC development.
regimens were administered in 84% of patients. Treatment duration was 12 weeks in 56% and 24 weeks in 36%; the remaining patients received different schedules (16-20 weeks) according to recommended treatments at that time.
Only 1 patient discontinued antiviral treatment because of a serious adverse event (sepsis). Overall, by intention-to-treat analysis, 546 (97%) patients achieved an SVR, whereas 11 patients relapsed and 7 were lost to follow-up before reaching the SVR time point. All 7 patients lost to follow-up had no previous HCC history.
Incidence, Features, and Predictors of De Novo Hepatocellular Carcinoma
After a median follow-up of 25 (3-39) months, 28 patients developed de novo HCC: the 6-month, 12-month, 18-month, and 2-and 3-year estimated incidence rates were 1.4%, 3.4%, 4.7%, 5.7%, and 6%, respectively ( Figure 2 ). Median time to HCC development was 11 (3-25) months; only 2 patients developed de novo HCC 3 months after DAA start (Supplementary Figure 1) .
At diagnosis, median HCC size was 21 (10-100) mm, single in 21 (75%) patients, diagnosed according to radiologic criteria in 93%. CPT score was A and BCLC 0-A in 23 (82%) patients. AFP value was 6 (1-9240) ng/mL: 11 (39%) had AFP >7 ng/mL, only 8 (29%) had AFP >20 ng/mL. Twenty-four (86%) patients were eligible for curative HCC treatments (liver transplantation in 8, resection in 8, radiofrequency ablation in 8), transarterial chemoembolization was performed in 3 patients, and 1 patient received only supportive treatment because of BCLC D stage (Table 2) .
At univariate analysis, de novo HCC was associated with male gender, diabetes, baseline g-glutamyltransferase values, CPT score, AFP levels, and LSM values. Despite limited patient numbers, when further substratifying CPT A patients according to history of previous ascites, the 3-year estimated cumulative incidence of de novo HCC was 6% (95% confidence interval [CI], 4%-8%) in CPT A versus 10% (95% CI, 2%-53%) in CPT A with previous ascites versus 12% (95% CI, 6%-24%) in CPT B patients (P ¼ .25). When CPT A patients with previous ascites were combined with CPT B patients, there was a trend toward higher de novo HCC incidence rates compared with CPT A patients, 6% (95% CI, 4%-9%) in CPT A versus 11% (95% CI, 6%-22%) in CPT A with previous ascites plus CPT B patients (P ¼ .09). De novo HCC incidence rates were also similar irrespective from how cirrhosis was diagnosed: 5% (95% CI, 2%-11%) for clinical diagnosis versus 6% (95% CI, 3%-15%) for histology versus 6% (95% CI, 4%-11%) for transient elastography (P ¼ .84).
At multivariate analysis, only male gender (hazard ratio [HR], 6.17; 95% CI, 1.44-26.47; P ¼ .01), diabetes Table 4 ). The 3-year estimated cumulative incidence of HCC was 9% in males versus 2% in females (P ¼ .0048), and 16% in patients with diabetes versus 4% in patients without diabetes (P ¼ .0001). By analyzing different cutoff of LSM, baseline LSM >30 kPa independently predicted de novo HCC, the 3-year estimated incidence of de novo HCC being 20% in patients with LSM >30 kPa versus 5% in patients with LSM 30 kPa (P ¼ .0003) (Figure 3 ).
In a model including aspartate aminotransferase to platelet ratio, FIB-4, and liver stiffness-spleen size-toplatelet but excluding LSM values, male gender (HR, 3.82; 95% CI, 1.29-11.35; P ¼ .02), diabetes (HR, 3.63; 95% CI, 1.69-7.82; P ¼ .001), and FIB-4 (HR, 1.08; 95% CI, 1.01-1.14; P ¼ .01) independently predicted de novo HCC (Supplementary Table 5 ). The 3-year estimated cumulative incidence of de novo HCC was 10% in patients with FIB-4 >9 versus 5% FIB-4 9, respectively (P ¼ .02) (Figure 3) .
By combining the independent predictors of de novo HCC, the HCC risk proportionally increased according to presence of additional predictors, ranging from 8% in patients with a single factor to 50% in case of the highest risk profile (Figure 4 ). De novo HCC development was not associated with treatment outcome, because HCC developed in 2/10 (20%) patients with HCV relapse compared with 26/487 (5.3%) patients achieving the SVR (P ¼ .10).
Incidence, Features, and Predictors of Recurrent Hepatocellular Carcinoma
Among the 60 patients with previous HCC, 20 developed HCC recurrence after a median follow-up of 23 (7-37) months. HCC recurred 12 (1-24) months after DAA start (Supplementary Figure 1) ; the 6-month, 12-month, 18-month, and 2-and 3-year estimated recurrence rates were 7%, 17%, 27%, and 43%, respectively (Figure 2 ). At diagnosis, HCC size was 15 (10-30) mm: HCC was single in 13 (55%) patients, <3 cm in all cases, bifocal in 3 (15%), and multifocal in 4 (20%). In 3 patients, HCC recurred with extrahepatic spread. HCC recurrence was diagnosed radiologically in 90% patients, CPT score was A in 18 (90%), and AFP was 9 (2-3064) ng/mL; AFP was >7 in 65% and >20 in 30% of the patients (Table 2) .
Patients with HCC recurrence were eligible to radical treatments in 55% of cases (liver transplantation in 4, resection in 1, radiofrequency ablation in 6); 5 patients were treated with transarterial chemoembolization, 2 received sorafenib, 1 was treated with PEI, and 1 patient underwent resection of an HCC localization in the gluteus muscle. There were no significant differences between features of de novo and recurrent HCC at diagnosis (Table 2) .
At univariate analysis, baseline body mass index, bilirubin values, and diabetes were associated with HCC recurrence. HCC recurrence rates did not differ if cirrhosis was diagnosed by clinical diagnosis versus histology versus transient elastography, being 54% (95% CI, 32%-80%), 41% (95% CI, 21%-69%), and 32% (95% CI, 10%-75%) (P ¼ .42), respectively. At multivariate analysis, only diabetes significantly predicted HCC recurrence (HR, 4.12; 95% CI, 1.55-10.93; P ¼ .004) (Supplementary Table 6 ). Indeed, the 3-year estimated incidence of recurrent HCC was 100% in patients with diabetes versus 34% in patients without diabetes (P ¼ .002). Neither previous HCC features nor time interval between HCC treatment and DAA start predicted HCC recurrence at univariate analysis. Indeed, HCC recurred in 7/17 (41%) patients starting DAA 6 months from previous HCC treatment versus 13/43 (30%) patients starting DAA treatment >6 months (P ¼ .54). HCC recurred within 3 months from DAA start only in 1 patient, who was diagnosed with HCC 1 month after antiviral treatment initiation: the patient had been treated for the previous HCC 66 months before, last CR being assessed 3 months before DAA administration. Moreover, recurrence rates did not differ according to number of treatments required to achieve the previous CR (38% CR achieved by 1 treatment vs 32% CR achieved by >1 treatment; P ¼ .76), and type of previous HCC treatment (curative vs noncurative treatments: 50% vs 31% respectively; P ¼ .39). Among the 13 patients receiving resection as previous HCC treatment, 2 patients had microvascular invasion at histology: both patients had HCC recurrence. HCC recurrence did not affect antiviral treatment outcome, because only 1 patient with HCC recurrence did not achieve the SVR.
Discussion
This single-center, longitudinal 3-year follow-up study, including 565 patients with cirrhosis treated with DAAs, reports rates of de novo and recurrent HCC of 2% and 13% per year, respectively. Being most HCC diagnosed in early stages, the majority of patients received curative HCC treatments. Moreover, male gender, diabetes, and liver stiffness or noninvasive markers of liver fibrosis were found to be the strongest and independent predictors of de novo HCC, whereas diabetes was the only predictor of HCC recurrence. To our knowledge, this is the first single-center study investigating HCC occurrence and recurrence in a large cohort of DAA-treated patients with cirrhosis with a long (median, 25 months) follow-up. More importantly, all patients were consecutively included, this resulting both by the single-center design and by specific Italian drug reimbursement rules that allowed treatment prescription only following a case-by-case authorization in a national web platform.
Concerning de novo HCC, our incidence rates are in line with most recent studies: indeed, 2 large retrospective American studies reported 1.82% and 1.97% per year de novo HCC incidence in SVR patients with cirrhosis, respectively, resulting in 71% HCC risk reduction following an SVR to DAA. 11, 12 In the Italian setting, the multicenter Navigator study reported 2% per year de novo HCC incidence in 2388 patients with cirrhosis treated with DAA during a median follow-up of 523 days, whereas in the RESIST-HCV dataset the incidence of de novo HCC was 1.69% per year in CPT A patients with cirrhosis followed for 34 (8-72) weeks. 5, 20 Unlike some previous concerns about increased biologic aggressiveness of HCC after DAA treatment, resulting in infiltrative pattern and multinodular tumors outside Milan criteria, 5 our de novo HCC were mostly single, small, and diagnosed in early stages, resulting in BCLC stage 0-A in the majority of patients. As a consequence, most patients were eligible to radical treatment options (liver transplantation, resection, radiofrequency ablation). In addition, results of our study do not support an accelerated HCC development under DAA treatment: indeed, median time to HCC onset was 11 months, 22/28 de novo HCC being diagnosed !6 months after DAA start. The potential bias of these results is the 6-month US surveillance performed in patients without HCC history, which could result in skipping some tumors in the early months following treatment start. However, a more intensive surveillance strategy for HCC is not currently supported by international recommendations; in addition, because in our study most patients presented with an early HCC stage, the need for an earlier detection seems questionable.
This is also the first study extensively analyzing predictors of HCC in the DAA-treated patients with cirrhosis, because of availability of complete information concerning both patients and tumor characteristics. In our analysis, we identify male gender and diabetes as independent predictors of de novo HCC, thus replicating the classical and historical HCC predictors identified in SVR patients with the interferon-based regimens 21 ; in addition, we report LSM !30 kPa or FIB-4 >9 being associated with HCC development. The predictive role of LSM was identified also by the Italian study of Conti et al, 7 where LSM !21.3 kPa predicted HCC development in 285 patients without HCC (odds ratio, 4.24; 95% CI, 1.50-11.97). Not surprisingly, increased LSM values suggest more advanced liver disease at baseline, by definition the subgroup of patients with the highest risk of HCC development. Besides LSM, we assessed other noninvasive tests easy to perform and widely available, such as aspartate aminotransferase to platelet ratio, FIB-4, and liver stiffness-spleen size-to-platelet demonstrating that FIB-4 independently predicted HCC.
Concerning patients with a previous HCC history, our results report 43% estimated HCC recurrence at 3 years (approximately 13% per year), although patient numbers are limited (n ¼ 60) and result in larger CIs of cumulative risk curves (21%-60%). These figures are similar to a large multicenter Italian study, reporting 26.6% 12-month HCC recurrence rates in 143 patients radically cured for a previous HCC 22 and to a recently published systematic review about HCC recurrence, reporting 25% (95% CI, 19%-31%) pooled HCC recurrence. 23 In our study, we provided broad information about features of the past HCC that was cured before DAA-treatment (BCLC stage, time intervals between previous HCC treatment and DAA start, definition of CR to HCC treatment, and number of imaging assessments between previous HCC treatment and DAA start). All these previous HCC features were assessed in the analysis aimed at identifying predictors of HCC recurrence; however, none of them predicted recurrence. This could be related to the small patient population with previous HCC, which could have prevented us from observing significant associations. In contrast with some reports, 7, 10, 24 as for de novo HCC, in our study we did not observe an accelerated HCC recurrence rate under DAA treatment, because median time to recurrence was 12 months and most HCC recurred after 6 months from treatment start. Of note, in our study median time between previous HCC treatment and DAA start was 12 months, so that most patients were able to perform at least 1 or 2 imaging techniques to assess complete HCC response, granting for including patients with consolidated CR at baseline.
Moreover, per study inclusion criteria, CR was defined as no evidence of HCC following 2 consecutive imaging assessments performed 1 and 3 months after previous HCC treatment. This definition of CR was not homogeneous in previous studies dealing with HCC recurrence, because most studies required only 1 negative imaging technique to define CR, 6, 7 so that this could at least partially account for differences observed in HCC recurrence rates. When considering the 3 patients with HCC recurrence within 6 months, only 1 had been previously treated for HCC 4 months before DAA start, whereas the others 22 and 66 months, respectively. Finally, we failed to detect increased rates of aggressive HCC recurrence patterns, because most patients were diagnosed in early stages, similarly to de novo HCC, and were eligible to radical treatment options.
In our study, SVR rates were very high compared with some previous reports, 97% by intention-to-treat analysis in the overall cohort: high treatment effectiveness did not allow to evaluate the potential relationship between treatment failure and HCC development, whereas according to study exclusion criteria and Italian reimbursement rules no patient with active HCC at baseline received antiviral treatment.
Major strengths of our study are the large patient cohort, the consecutive enrolment, the long follow-up, availability of complete information about HCC features and treatment, and homogeneous HCC screening policies and diagnosis. Careful exclusion of patients with active HCC at baseline or undefined liver nodules allowed eliminating the cohort effect observed in other studies, where increased HCC onset early soon after DAA start could be explained with inclusion of patients with active or not radically cured HCC.
We acknowledge that our study suffers from some limitations. First is small patient number in the group with a previous history of HCC. In addition, Italian DAA prescription rules excluded patients with CPT score C outside the liver transplant waiting list, whose risk of HCC is certainly higher, so that a potential underestimation of HCC incidence in patients with more advanced liver disease cannot be excluded. Another potential limitation of the study could be that in 319 (56%) patients, diagnosis of cirrhosis was obtained by transient elastography with an LSM cutoff >11.9 kPa, which could lead to include also patients with bridging fibrosis and consequently lower the risk of HCC in the cohort. However, the 12-kPa cutoff has been already used by other published papers concerning HCC and DAA. 7, 20, 22 Moreover, cumulative incidences of HCC were similar irrespectively from how cirrhosis was diagnosed.
In conclusion, in a large single-center cohort of HCV patients with cirrhosis treated with DAA, we demonstrate that both de novo and recurrent HCC developed in early stages, resulting in eligibility to radical treatment options. We identify male gender, diabetes, and noninvasive markers of liver fibrosis as independent predictors of de novo HCC, diabetes predicting also HCC recurrence. Residual risk of HCC in patients with cirrhosis calls for continued surveillance in this patient population after the achievement of the SVR. 
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